TheraRadar

Pharma Intelligence, Simplified

Landscape → CNS

Alzheimer's Disease

966 clinical trials

368 active
/
966 total (since 2015)
105
Phase 1 Active
329 total
199
Phase 2 Active
500 total
85
Phase 3 Active
188 total
34
Phase 4 Active
70 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Eli Lilly 10 11 3
Bristol-Myers Squibb 8 0 0
Roche 6 9 10
Luye Pharma Group Ltd. 5 1 0
ACADIA Pharmaceuticals Inc. 4 2 1
Karuna Therapeutics 4 0 0
Eisai Inc. 3 4 0
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. 3 0 1
Regeneration Biomedical, Inc. 3 0 0
Merck 2 11 2
Novartis 2 3 3
Denali Therapeutics Inc. 2 1 0
GSK 2 0 1
Intra-Cellular Therapies, Inc. 2 0 1
NKGen Biotech, Inc. 2 0 1
NCT07284472 RECRUITING
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Exciva GmbH n=300
NCT07011732 RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb n=352
NCT07011745 RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Bristol-Myers Squibb n=352
NCT06194799 ENROLLING BY INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACADIA Pharmaceuticals Inc. n=752
NCT07084831 RECRUITING
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
European Group for Research In Schizophrenia n=171
NCT06709014 RECRUITING
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Annovis Bio Inc. n=760
NCT06585787 RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics n=406
NCT06937229 RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb n=600
NCT07422311 NOT YET RECRUITING
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
Benuvia Therapeutics Inc. n=140
NCT07095465 ENROLLING BY INVITATION
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc. n=126
NCT06159673 RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc. n=1,074
NCT05303701 NOT YET RECRUITING
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Samsung Pharmaceutical Co., Ltd. n=750
NCT07422857 RECRUITING
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
JYAMS PET Research & Development Limited n=316
NCT05511363 RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics n=380
NCT04661280 RECRUITING
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Assistance Publique - Hôpitaux de Paris n=240
NCT06125951 ACTIVE NOT RECRUITING
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Actinogen Medical n=247
NCT05980949 RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics n=800
NCT07170150 RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche n=800
NCT06976203 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb n=586
NCT05269394 ACTIVE NOT RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Washington University School of Medicine n=197
NCT06647498 RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine n=280
NCT05552157 RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine n=280
NCT06384573 ACTIVE NOT RECRUITING
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Washington University School of Medicine n=43
NCT05508789 RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Eli Lilly and Company n=1,500
NCT06976216 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb n=586
NCT07142954 RECRUITING
Epidemiology and Biomarker Study in Alzheimer's Disease
Eli Lilly and Company n=3,400
NCT07177352 RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche n=13,000
NCT07062198 RECRUITING
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
ScandiBio Therapeutics AB n=845
NCT07169578 RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche n=800
NCT04777396 ACTIVE NOT RECRUITING
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Novo Nordisk A/S n=1,840
NCT04516057 RECRUITING
Nabilone for Agitation Blinded Intervention Trial
Sunnybrook Health Sciences Centre n=112
NCT03860857 RECRUITING
Biomarker Exploration in Aging, Cognition and Neurodegeneration
University of California, Irvine n=300
NCT05230758 RECRUITING
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
Donald Mabbott n=140
NCT05026866 ACTIVE NOT RECRUITING
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company n=2,996
NCT05397639 RECRUITING
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Suven Life Sciences Limited n=375
NCT04468659 ACTIVE NOT RECRUITING
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Eisai Inc. n=1,400
NCT07234695 RECRUITING
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=120
NCT07284316 ACTIVE NOT RECRUITING
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.
Instituto Mexicano del Seguro Social n=100
NCT05641688 RECRUITING
[18F]PI-2620 Phase 3 Histopathological Study
Life Molecular Imaging Ltd n=200
NCT07323914 RECRUITING
Clinical Analgesic Management in Dementia
Xuanwu Hospital, Beijing n=10
NCT05470816 ACTIVE NOT RECRUITING
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial
Bayside Health n=826
NCT06534723 RECRUITING
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
Sichuan Jishengtang Pharmaceutical Co., Ltd. n=570
NCT06797817 NOT YET RECRUITING
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
Universidad de Almeria n=156
NCT07251023 RECRUITING
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
Bigespas LTD n=450
NCT05809908 NOT YET RECRUITING
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Cerecin n=535
NCT07083154 RECRUITING
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=420
NCT06653153 ACTIVE NOT RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company n=1,400
NCT05738486 ACTIVE NOT RECRUITING
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company n=1,175
NCT05532657 ACTIVE NOT RECRUITING
ACHIEVE Brain Health Follow-Up Study
Johns Hopkins University n=629
NCT05456503 RECRUITING
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
University of Pennsylvania n=72
NCT06304883 ACTIVE NOT RECRUITING
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Alzheon Inc. n=163
NCT03887455 ACTIVE NOT RECRUITING
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Eisai Inc. n=1,906
NCT05564169 NOT YET RECRUITING
Masitinib in Patients With Mild Alzheimer's Disease
AB Science n=600
NCT05531526 ACTIVE NOT RECRUITING
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
AriBio Co., Ltd. n=1,535
NCT03121209 ACTIVE NOT RECRUITING
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)
Columbia University n=385
NCT06191965 RECRUITING
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Mclean Hospital n=100
NCT07191028 NOT YET RECRUITING
Alzheimer's Disease THErapy With NEuroaid II
Moleac Pte Ltd. n=350
NCT04437511 ACTIVE NOT RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company n=1,736
NCT06950190 ENROLLING BY INVITATION
Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)
Ellis Medicine n=100
NCT07115238 RECRUITING
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
Sinotau Pharmaceutical Group n=354
NCT06996730 NOT YET RECRUITING
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Banner Health n=240
NCT06254469 RECRUITING
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CereMark Pharma, LLC n=230
NCT07066826 NOT YET RECRUITING
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Wanbangde Pharmaceutical Group Co., LTD n=720
NCT07060391 NOT YET RECRUITING
A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease
Shanghai Jiao Tong University School of Medicine n=186
NCT06566183 NOT YET RECRUITING
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
NYU Langone Health n=1,200
NCT05983575 ACTIVE NOT RECRUITING
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
Sound Wave Innovation CO., LTD. n=220
NCT06964230 NOT YET RECRUITING
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
T3D Therapeutics, Inc. n=376
NCT06947941 NOT YET RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb n=1,046
NCT05463731 ACTIVE NOT RECRUITING
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company n=1,667
NCT04570085 RECRUITING
Effect of CAFfeine on Cognition in Alzheimer's Disease
University Hospital, Lille n=248
NCT04904536 ACTIVE NOT RECRUITING
Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy
The George Institute n=190
NCT06126224 ACTIVE NOT RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Karuna Therapeutics n=400
NCT04098666 ACTIVE NOT RECRUITING
Metformin in Alzheimer's Dementia Prevention
Columbia University n=326
NCT06120049 RECRUITING
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
prof. dr. Koen Van Laere n=113
NCT03108846 ACTIVE NOT RECRUITING
Escitalopram for Agitation in Alzheimer's Disease
JHSPH Center for Clinical Trials n=187
NCT06702124 RECRUITING
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
I.R.C.C.S. Fondazione Santa Lucia n=348
NCT06530732 RECRUITING
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
Zhejiang Provincial People's Hospital n=60
NCT03804229 ACTIVE NOT RECRUITING
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
Capital Medical University n=707
NCT03848312 RECRUITING
Preventing Alzheimer's With Cognitive Training
University of South Florida n=7,600
NCT06514066 NOT YET RECRUITING
Cannabidiol's Role in Dementia Management
Hospital Pengajar Universiti Putra Malaysia n=486
NCT05267535 ACTIVE NOT RECRUITING
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Neurim Pharmaceuticals Ltd. n=225
NCT03116126 ACTIVE NOT RECRUITING
Noradrenergic Add-on Therapy With Guanfacine
Imperial College London n=148
NCT05976152 RECRUITING
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Fudan University n=3,200
NCT04390646 RECRUITING
GnRH Therapy on Cognition in Down Syndrome
Nelly Pitteloud n=56
NCT05143528 NOT YET RECRUITING
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
KeifeRx, LLC n=1,275
NCT05891496 COMPLETED
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Novo Nordisk A/S n=23
NCT06736509 TERMINATED
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Axsome Therapeutics, Inc. n=139
NCT05894954 COMPLETED
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
Alzheimer's Prevention and Reversal Project, Inc. n=73
NCT03789760 COMPLETED
The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule
Shineway Pharmaceutical Co.,Ltd n=493
NCT04374136 TERMINATED
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Alector Inc. n=119
NCT05271552 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
BioXcel Therapeutics Inc n=151
NCT04947553 COMPLETED
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=456
NCT05557409 COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=408
NCT04770220 COMPLETED
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Alzheon Inc. n=325
NCT02446132 TERMINATED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,197
NCT05026177 TERMINATED
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Cassava Sciences, Inc. n=1,125
NCT05542953 COMPLETED
[18F]APN-1607 PET in Subjects With AD Compared to HC
APRINOIA Therapeutics n=230
NCT03446001 COMPLETED
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
TauRx Therapeutics Ltd n=598
NCT05256134 TERMINATED
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
Hoffmann-La Roche n=25
NCT04464564 TERMINATED
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=241
NCT04408755 TERMINATED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=184
NCT04994483 COMPLETED
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
Cassava Sciences, Inc. n=804
NCT05575076 TERMINATED
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Cassava Sciences, Inc. n=1,081
NCT05686044 COMPLETED
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
Annovis Bio Inc. n=351
NCT05310071 TERMINATED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Biogen n=1,027
NCT02360215 COMPLETED
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NRG Oncology n=518
NCT04488419 COMPLETED
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
LeonaBio n=554
NCT04886063 TERMINATED
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
LeonaBio n=423
NCT03554265 COMPLETED
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
The University of Texas Medical Branch, Galveston n=72
NCT04241068 TERMINATED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Biogen n=1,696
NCT06424236 TERMINATED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
Washington University School of Medicine n=73
NCT05432206 COMPLETED
MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva
Fondation pour l'accueil et l'hébérement des personnes âgées n=27
NCT05749939 COMPLETED
Acceptance Commitment Therapy for Caregivers of People with Memory Loss
Utah State University n=121
NCT05108922 COMPLETED
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Eli Lilly and Company n=148
NCT02719327 COMPLETED
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
VA Office of Research and Development n=131
NCT03393520 COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=601
NCT03620981 COMPLETED
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=410
NCT04552041 COMPLETED
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Materia Medica Holding n=406
NCT04771299 TERMINATED
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
Lakshmi N Yatham n=1
NCT03724942 COMPLETED
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=164
NCT04314934 COMPLETED
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Anavex Life Sciences Corp. n=300
NCT05239663 TERMINATED
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
Sun Yat-sen University n=76
NCT04395339 TERMINATED
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Sun Yat-sen University n=51
NCT03682185 COMPLETED
The Healthy Patterns Sleep Study
University of Pennsylvania n=421
NCT03486938 COMPLETED
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
AgeneBio n=164
NCT04374253 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
Hoffmann-La Roche n=1,382
NCT05015803 COMPLETED
Enhanced CBTi for Older Adult Sleep and Cognition
Penn State University n=60
NCT03444870 TERMINATED
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Hoffmann-La Roche n=1,053
NCT04339413 TERMINATED
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
Hoffmann-La Roche n=116
NCT03443973 TERMINATED
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Hoffmann-La Roche n=975
NCT05665088 TERMINATED
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
BioXcel Therapeutics Inc n=13
NCT04797715 COMPLETED
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=178
NCT04669028 COMPLETED
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
BioVie Inc. n=439
NCT03594123 COMPLETED
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=259
NCT03548584 COMPLETED
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=345
NCT03226522 COMPLETED
Addressing Dementia Via Agitation-Centered Evaluation
Axsome Therapeutics, Inc. n=366
NCT03691519 COMPLETED
Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells
University Hospital, Toulouse n=774
NCT02346201 COMPLETED
Apathy in Dementia Methylphenidate Trial 2
Johns Hopkins Bloomberg School of Public Health n=200
NCT04187547 WITHDRAWN
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
Cerecin
NCT03823404 COMPLETED
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Cortexyme Inc. n=643
NCT02442765 COMPLETED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=387
NCT04520412 SUSPENDED
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. n=2,046
NCT02442778 COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=522
NCT03986424 COMPLETED
Local Study of Akatinol Memantine in VaD in Russia
Merz Pharmaceuticals GmbH n=130
NCT03790709 COMPLETED
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Anavex Life Sciences Corp. n=509
NCT03721705 COMPLETED
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
Renew Research, LLC n=190
NCT03628391 TERMINATED
Haloperidol for Delirium in Adult Critically Ill Patients
Erasmus Medical Center n=142
NCT02913664 COMPLETED
Risk Reduction for Alzheimer's Disease
University of Texas Southwestern Medical Center n=513
NCT02547818 COMPLETED
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
AZTherapies, Inc. n=620
NCT02484547 TERMINATED
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Biogen n=1,643
NCT02477800 TERMINATED
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Biogen n=1,653
NCT02159027 COMPLETED
Maraviroc and NeuroAIDS Pathogenesis
University of Hawaii n=48
NCT03131453 TERMINATED
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Novartis Pharmaceuticals n=1,145
NCT02565511 TERMINATED
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Novartis Pharmaceuticals n=480
NCT02817906 TERMINATED
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Intra-Cellular Therapies, Inc. n=177
NCT03325556 COMPLETED
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
ACADIA Pharmaceuticals Inc. n=392
NCT02916056 TERMINATED
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
vTv Therapeutics n=297
NCT02080364 TERMINATED
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
vTv Therapeutics n=880
NCT03031184 COMPLETED
Study of Mirtazapine for Agitation in Dementia
University of Sussex n=207
NCT03785067 TERMINATED
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
The George Institute n=1
NCT03815292 COMPLETED
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
Materia Medica Holding n=276
NCT03197740 COMPLETED
A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
Icure Pharmaceutical Inc. n=399
NCT02956486 TERMINATED
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Eisai Co., Ltd. n=2,212
NCT03075241 COMPLETED
Z-Drugs for Sleep Disorders in Alzheimer's Disease
Brasilia University Hospital n=62
NCT02248636 COMPLETED
Cholinesterase Inhibitor Discontinuation
VA Office of Research and Development n=72
NCT03901092 COMPLETED
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
Avid Radiopharmaceuticals n=242
NCT02516046 COMPLETED
18F-AV-1451 Autopsy Study
Avid Radiopharmaceuticals n=156
NCT03901105 COMPLETED
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Avid Radiopharmaceuticals n=205
NCT03114657 TERMINATED
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Hoffmann-La Roche n=806
NCT02670083 TERMINATED
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
Hoffmann-La Roche n=813
NCT03491150 TERMINATED
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
Hoffmann-La Roche n=149
NCT02351882 COMPLETED
Safety and Efficacy of Nabilone in Alzheimer's Disease
Sunnybrook Health Sciences Centre n=38
NCT02350127 COMPLETED
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
VA Office of Research and Development n=88
NCT02586909 TERMINATED
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
Axovant Sciences Ltd. n=1,099
NCT04318639 COMPLETED
The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
VA Connecticut Healthcare System n=15
NCT02353949 TERMINATED
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
University of Zurich n=11
NCT02972658 TERMINATED
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
AstraZeneca n=421
NCT02783573 TERMINATED
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
AstraZeneca n=1,722
NCT02750306 COMPLETED
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
Merck Sharp & Dohme LLC n=285
NCT02760602 TERMINATED
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Eli Lilly and Company n=26
NCT03620253 TERMINATED
Modafinil's Effects on Cognition in Remitted MDD
Unity Health Toronto n=9
NCT02284906 TERMINATED
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Takeda n=40
NCT03010865 WITHDRAWN
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Shanghai Mental Health Center
NCT02585934 COMPLETED
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
Axovant Sciences Ltd. n=1,315
NCT02317250 WITHDRAWN
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
University of California, Los Angeles
NCT02928445 TERMINATED
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
Axovant Sciences Ltd. n=240
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT02830854 COMPLETED
Molecular Hydrogen for Cognitive Function and Performance in Elderly
University of Novi Sad, Faculty of Sport and Physical Education n=13

Data: ClinicalTrials.gov